In this episode of No Priors, host Elad Gil interviews Brian Armstrong, co-founder and CEO of Coinbase and co-founder of New Limit. Armstrong outlines Coinbase's transition toward an 'Everything Exchange' offering multi-asset trading, tokenized traditional securities, stablecoin payments, and prediction markets.
A central focus of the discussion is 'Agentic Finance' (AI-fi). Armstrong highlights that over 70% of autonomous AI agent transactions fall below 30 cents, making legacy payment networks with flat 30-cent credit card fees unusable. Coinbase is addressing this by equipping AI agents with self-custodial crypto wallets and developing open protocols like x402 alongside partners like Google, Cloudflare, and AWS to power micro-payments across the web.
Internally, Coinbase is building automated 'brains' for software repositories that log technical history, financial controls, and past incident reports. These systems allow AI agents to propose code changes and learn recursively from engineer pull request reviews, boosting developer velocity.
Finally, Armstrong details New Limit, a biotechnology company he co-founded to reverse cellular aging through epigenetic reprogramming. Using AI models to navigate vast transcription factor search spaces, New Limit runs high-throughput screens in human cell models and plans to initiate its first human Phase 1 clinical trial for alcoholic liver disease next year. Armstrong concludes with policy recommendations, advocating for US 'Freedom Cities' on federal land to serve as regulatory sandboxes for hard-tech innovation.